Long-term adherence to statin treatment in diabetes

被引:67
作者
Donnelly, L. A. [1 ]
Doney, A. S. F. [2 ]
Morris, A. D. [3 ,4 ]
Palmer, C. N. A. [5 ]
Donnan, P. T. [6 ]
机构
[1] Univ Dundee, Div Commun Hlth Sci, Dundee DD2 4BF, Scotland
[2] Univ Dundee, Div Med & Therapeut, Dundee DD2 4BF, Scotland
[3] Univ Dundee, Div Med, Ninewells Hosp, Dundee DD2 4BF, Scotland
[4] Univ Dundee, Therapeut & Hlth Informat Ctr, Ninewells Hosp, Dundee DD2 4BF, Scotland
[5] Univ Dundee, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee DD2 4BF, Scotland
[6] Univ Dundee, Div Commun Hlth Sci, Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland
关键词
adherence; diabetes; population; statins;
D O I
10.1111/j.1464-5491.2008.02476.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To determine the patterns and predictors of long-term adherence to statin therapy in all patients with diabetes in the community setting. Methods We retrospectively studied patients with diabetes who were resident in Tayside, Scotland from 1 January 1989 to 31 May 2003 and initiated statin treatment during that time. The main outcome measure was percentage of days covered (PDC) by a statin, calculated at regular intervals. Predictors of suboptimal adherence (PDC < 80%) were identified using generalized linear models for repeated measures. Results Six thousand four hundred and sixty-two patients were included in the study. In the first year, the mean PDC was 87, 61% in the first and second quarter, respectively, and 65% after 13 years. Less than 50% of patients maintained a PDC of > 80% after 13 years. Predictors of poor long-term adherence were younger age, higher HbA(1c), no history of smoking, no cardiovascular morbidity at baseline and occurrence of cardiovascular disease after statin commencement. Conclusions This study suggests that barriers to long-term adherence to statins tend to arise early on in the therapeutic course. In general, long-term adherence is poor in patients with diabetes, especially among those with few other cardiovascular risk factors.
引用
收藏
页码:850 / 855
页数:6
相关论文
共 29 条
[1]   DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS [J].
ANDRADE, SE ;
WALKER, AM ;
GOTTLIEB, LK ;
HOLLENBERG, NK ;
TESTA, MA ;
SAPERIA, GM ;
PLATT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1125-1131
[2]   Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[3]   Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].
Beckman, JA ;
Creager, MA ;
Libby, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581
[4]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[5]   Predictors of adherence with antihypertensive and lipid-lowering therapy [J].
Chapman, RH ;
Benner, JS ;
Petrilla, AA ;
Tierce, JC ;
Collins, SR ;
Battleman, DS ;
Schwartz, JS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1147-1152
[6]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[7]   Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials [J].
Costa, Joao ;
Borges, Margarida ;
David, Claudio ;
Carneiro, Antnio Vaz .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7550) :1115-1118C
[8]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[9]  
Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177
[10]   Improved treatment of coronary heart disease by implementation at a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) [J].
Fonarow, GC ;
Gawlinski, A ;
Moughrabi, S ;
Tillisch, IH .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (07) :819-822